Hepatitis C Viral Dynamics Using a Combination Therapy of Interferon, Ribavirin, and Telaprevir: Mathematical Modeling and Model Validation by Aston, Philip et al.
Chapter 10
Hepatitis C Viral Dynamics Using a Combination
Therapy of Interferon, Ribavirin, and Telaprevir:
Mathematical Modeling and Model Validation
Philip Aston, Katie Cranfield, Haley O’Farrell,
Alex Cassenote, Cassia J. Mendes-Correa,
Aluisio Segurado, Phuong Hoang,
George Lankford and Hien Tran
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.75761
Provisional chapter
l ics si a bination
r , i avirin, and Telaprevir:
li el alidation
Philip Aston, Katie Cranfield, Haley O’Farrell,
Alex Cassenote, Cassia J. endes-Correa,
luisio Segurado, Phuong oang,
r L f r i r
Additional infor ation is available at the end of the chapter
Abstract
Groundbreaking new drugs called direct acting antivirals have been introduced recently for
the treatment of chronic Hepatitis C virus infection. We introduce a mathematical model for
Hepatitis C dynamics treated with the direct acting antiviral drug, telaprevir, alongside
traditional interferon and ribavirin treatments to understand how this combination therapy
affects the viral load of patients exhibiting different types of response. We use sensitivity and
identifiability techniques to determine which model parameters can be best estimated from
viral load data. Parameter estimation with these best estimable parameters is then performed
to give patient-specific fits of the model to partial virologic response, sustained virologic
response and breakthrough patients.
Keywords: hepatitis C dynamics, inverse problem, subset selection, sensitivity analysis,
identifiability analysis, automatic differentiation
1. Introduction
Over 200–300 million people worldwide are infected with a virus called Hepatitis C (HCV)
that affects the liver, which was discovered in 1989 [1]. It is usually spread by blood-to-blood
contact via intravenous drug use, poorly sterilized medical equipment and transfusions.
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Scarring of the liver and ultimately cirrhosis are just a few of the more severe complications
associated with HCV [2].
Six different genotypes of HCV exist due to the highly error prone RNA polymerase with the
most common being genotype 1 that has the lowest levels of response to standard treatment [3, 4].
Genotype 1 patients have about a 50% chance for sustained virologic response (SVR), while non-
genotype 1 patients have about an 80% chance for SVR [5]. The clinical data used for this study
were provided by the University of Sao Paulo, School of Medicine in Sao Paulo, Brazil and consist
of genotype 1 patients.
One of the first treatments for HCV was 6–12 months monotherapy with interferon glyco-
proteins. Interferon is naturally secreted from our bodies to fight off infection and
monotherapy treatment with them is associated with around 10% SVR [6]. The addition of
ribavirin (RBV), a drug believed to render some of the virus non-infectious, increased SVR
to around 30% [6]. RBV monotherapy is not recommended because it does not give a
significant benefit to SVR [7]. Until recently, the most common therapy was a combination
of pegylated Interferon (IFN) and RBV for 24–48 weeks that yielded about a 45% SVR [5, 6].
One of the major differences between IFN and standard inteferon glycoproteins is that the
pegylation allows the drugs to stay in the body longer [8]. There have also been clinical
trials with RBV monotherapy before and after IFN + RBV therapy as described in [9].
Recently, new drugs called direct-acting antiviral agents (DAAs) have raised the chance
for SVR for HCV patients.
DAAs give an increase to about an 80% chance for SVR for genotype 1 [10]. According to the
FDA, DAAs are drugs that interfere with specific steps in the HCV replication cycle by taking
advantage of the biological makeup of HCV [11]. HCV is a single-stranded RNAmolecule that
is several nucleotides in length. During HCV’s life cycle, it is translated into a polyprotein that
is composed into structural and nonstructural proteins that aid in replication. During post-
translational processing, DAAs called protease inhibitors block a key protease from the repli-
cation process and hinders further infection [10, 12]. Among the protease inhibitors available
are boceprevir, telaprevir and simeprevir. Simeprevir is recommended over telaprevir and
boceprevir because of both improved efficacy and less side effects, but telaprevir continues to
be used because of its cost efficiency [13, 14].
Integration of mathematical modeling of viral dynamics with clinical data has led to further
understanding of how different treatment strategies dictate viral load dynamics. One of the
first mathematical models was given by Neumann et al. which attempted to describe HCV
dynamics with interferon monotherapy [4]. Improvements were made to the Neumann’s
model to better describe different mechanisms in the liver during treatment including the
regeneration of liver cells. Adjustments were also made to include the standard of care,
IFN, and RBV. Some of these modifications can be found in [5, 15]. In particular, Snoeck
et al. [5] had data after the end of the treatment phase so that the model can give a more
accurate representation of its prediction of SVR. The introduction of DAAs has ushered in
more mathematical models that include this type of therapy [16]. For example, mathemat-
ical models have been proposed using telaprevir monotherapy [17–20] and in combination
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with IFN and RBV [18] that uses Bayesian feedback to estimate the parameters in the
model. The challenges that come with modeling DAAs is that since they are relatively
new, there is not as much data available [17]. It can be difficult to predict SVR because of a
lack of data after the treatment phase ends due to how recent the drugs have been
approved.
This chapter introduces a novel approach for the development of a mathematical model
describing HCV dynamics given the triple-drug combination treatment of IFN, RBV, and the
DAA telaprevir. In Section 2, we describe how we adapted a previously known HCV model to
include telaprevir and the available clinical data. Section 3 describes the a priori analysis of
sensitivity and identifiability and its incorporation into the parameter estimation problem.
Section 4 gives the parameter estimation results using several patient specific clinical data
including partial virologic response, sustained virologic response and breakthrough. Finally,
concluding remarks are provided in Section 5.
2. Mathematical models of HCV dynamics
The original model for HCV dynamics in Neumann et al. [4] was frequently used to assess
viral-load profiles after short-term treatment and is given by
dT
dt
¼ s dT  1 ηð ÞβVT,
dI
dt
¼ 1 ηð ÞβVT  δI,
dV
dt
¼ 1 εð ÞpI  cV,
(1)
where T and I denote the concentrations of healthy and infected hepatocytes, and V
represents viral concentration in the liver fluid. One of the key contributions of the model
was the understanding of the mechanism of IFN. It was unknown whether it acted
through η > 0 (i.e., inhibiting the infection of healthy liver cells) or ε > 0 (i.e., reducing
virion production in infected cells). In [4], it is determined that it is through ε which
inhibits production of the virus. The drawback to (1) is that it cannot describe patients
exhibiting breakthrough, relapse, and most importantly SVR. These responses are reasons
that early viral response does not uniformly predict responses in the long term. Another
important aspect is the handling of viral load measurements below the lower limit of
quantification (LLOQ). Previous analysis omitted the data below LLOQ, but it can contain
critical information regarding long-term treatment outcome. Snoeck et al. [5] present a
mathematical model for the dynamics of HCV with the drug treatment combination of
IFN and RBV that attempts to address both the long-term responses and the use of the
LLOQ. The model described in [5] is given by the following system of nonlinear differen-
tial equations
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dT
dt
¼ sþ rT 1 T þ I
Tmax
 
 dT  βVIT, b
dI
dt
¼ βVIT þ rI 1 T þ ITmax
 
 δI,
dVI
dt
¼ 1 rð Þ 1 εð ÞpI  cVI,
dVNI
dt
¼ r 1 εð ÞpI  cVNI,
(2)
where T (uninfected hepatocytes), I (infected hepatocytes), VI (infectious virions) and VNI
(noninfectious virions) are natural states (international units IU/mL). This model was adapted
from a standardmodel of viral infection [4]. The number of uninfected hepatocytes increases each
day with reproduction rate s and regeneration rate r. That number decreases each day as those
hepatocytes die naturally at a rate d or infected at a rate β. The maximum number of hepatocytes
per mL is Tmax. The number of infected hepatocytes increases when the healthy liver cells are
infected andwhen the infected cells regenerate themselves. That number decreases when they die
off naturallyat a rate δ. Infectedhepatocytes produce both infectious andnoninfectious virions at a
rate p. Virions are naturally cleared at a rate c. IFN inhibits virus production while RBV renders
some of the virus noninfectious. The drug efficacies of IFN and RBV are represented by ε and r,
respectively. The bounds for IFN and RBVare 0 < ε ≤ 1 and 0 < r ≤ 1 where themore effective the
drug is, the closer the efficacy of the drug will be to 1. Snoeck uses data that extend beyond
treatment for patients so the terms ε and r in (2) account for the exponential decays of the efficacies
of the drugs after treatment has ceased. The exponential decay of the drug efficacies is given by
ε ¼ εek ttendð Þþ , (3)
and
r ¼ rek ttendð Þþ , (4)
where k is the efficacy decay rate, tend marks the end of treatment, and
að Þþ ¼
a if a ≥ 0,
0 otherwise:

The drug efficacies ε and r are related to the drug dosage levels by the following expressions
ε ¼ DosePEG
ED50PEG þDosePEG
, (5)
and
r ¼ DoseRBV
ED50RBV þDoseRBV
, (6)
where Dose PEG is the weekly subcutaneous dose of IFN and ED50PEG is the estimated weekly
dose that causes 50% inhibition of virion production. DoseRBV represents the daily dose of
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RBV/kg body weight, and ED50RBV represents the estimated daily dose in mg/kg that makes
50% of the virions noninfectious. Biologically, all state variables and parameters are non-
negative. Typical values for model parameters used by Snoek et al. [5] are given in Table 1.
2.1. HCV model with DAA
Snoeck’s model is adapted to incorporate the DAA, telaprevir. Recall that a DAA targets
specific parts of the genome of the virus to inhibit both replication and infection. The hindrance
of replication of the virus in the infected hepatocytes results in the virus not being produced by
those cells. This means that the DAA should be implemented as part of the infection term,
βTVI , for inhibiting infection and viral production terms, pVI and pVNI , for inhibiting replica-
tion of the virus in (2). However, after simulations and analysis, it is concluded in this study
that the obstruction of the infection and replication of the virus by telaprevir can be described
solely as an amplifier for mitigating the production of virions alongside IFN. With this
assumption, the model in [5] is modified to include the triple drug combination of IFN, RBV
and telaprevir as follows:
_T ¼ sþ rT 1 T þ I
Tmax
 
 dT  βVIT
_I ¼ βVIT þ rI 1 T þ ITmax
 
 δI
_VI ¼ 1 rð Þ 1 εð Þ 1 γð ÞpI  cVI
_VNI ¼ r 1 εð Þ 1 γð ÞpI  cVNI,
(7)
where γ represents the exponential decay of the telaprevir efficacy and is defined similarly
as for ε and r (see (3) and (4)). In [21], existence and uniqueness of solutions to this updated
Parameter Value
s 6:17 104 hepatocytemLday
r .00562 day1
β 8:7 109 mLvirionday
δ .139 day1
c 4.53 day1
Tmax 1:85 107 hepatocytesmL
d .003 day1
p 25.1 virionshepatocyteday
ε .896
r .4–.6
k .0238 day1
Table 1. Typical values from [5].
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HCV dynamical model were established, and a steady-state stability analysis was also
performed.
2.2. Treatment schedule
The data in this research uses the treatment schedule timeline as follows (also summarized in
Figure 1).
1. The patient is treated with the triple drug combination of IFN + RBV + telaprevir for the
first 12 weeks.
2. If at 12 weeks, viral load > 1000 IU/mL, then discontinue treatment. Otherwise, continue
12-week treatment of IFN + RBV.
3. If at 24 weeks, viral load > LLOQ (12–15 IU/mL), then discontinue treatment. Otherwise,
continue 12-week treatment of IFN + RBV.
4. If at 36 weeks, viral load > LLOQ, then discontinue treatment. Otherwise, continue 12-
week treatment of IFN + RBV.
5. End of treatment at 48 weeks.
3. Subset selection
The forward problem refers to using a model to predict the future behavior of a system given
a set of parameters. The inverse problem, on the other hand, is the parameterization of a model
from empirical data [22–24]. There have been extensive studies about parameter selection
while solving the inverse problem for biological models and other applications that can be
found in [3, 22, 25–27] and references therein. In this study, we use a simple algorithm to
choose a subset of parameters to be estimated from clinical data based on both sensitivity and
identifiability as follows:
1. Start with the full parameter set Q.
2. Remove parameters that are not locally sensitive to attain QS ⊂Q.
3. Remove parameters that are not locally identifiable from QS to obtain sensitive and
identifiable parameter set QSI
Figure 1. Treatment schedule for patients used for data received from patients treated at University of Sao Paulo, School
of Medicine in Sao Paulo, Brazil.
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Since these are local analyses, this procedure is repeated over a large number of parameter sets
and the parameters that appear most often in QSI are the parameters that are estimated. All
other parameter values are fixed to values from the literature. A biological and structural
explanation for some of the fixed parameters is given in the next section.
3.1. Fixed parameters
The assumptions for fixed parameters are the same as in [5]. Since the maximum number of
hepatocytes in the liver is 2:50 1011 and HCV RNA is distributed in plasma and extracellular
fluids with a volume of  1:35 104 ml, then Tmax ¼ 2:5010111:35104 ¼ 1:85 107. d is obtained from
hepatocyte turnover being every 300 days and s ¼ Tmax  d can be deduced in the absence of
liver disease. p is always fixed because p 1 εð Þ appears in _V and _VNI making p and ε,
impossible to estimate uniquely. The rest of the parameters will be considered in the sensitivity
analysis.
3.2. Sensitivity analysis
A sensitivity analysis is the process of understanding how the model output is affected by
changes in the parameters. Sensitivity analyses are used in many branches of mathematics
such as statistics, partial differential equations (PDEs), and control design [28, 29]. The param-
eters that give the most change in the output are said to be sensitive parameters. This is
important in the forward problem because it allows an understanding of which parameters will
give useful information. Once the parameters have been identified, a sensitivity analysis for the
inverse problem is usually performed to determine the sensitive parameters. Parameters with
minimal impact are fixed from the literature. There are two different types of sensitivity
analysis: global and local. A global sensitivity analysis heavily depends on the structure of
the model and quantifies how uncertainties in outputs can be apportioned to uncertainties in
inputs. We refer the reader to [30] for a more comprehensive discussion. Our study uses a local
sensitivity analysis that depends on the prescribed values of the parameters.
3.2.1. Sensitivity equations
The sensitivity analysis presented in this section uses a derivative-based approach. Consider
the general form of an ODE model and a function z of its output
dy
dt
¼ f t; y; qð Þ,
z ¼ g t; y; qð Þ,
(8)
whereby the vectors y and q contain the variables and parameters of the model, respectively.
Since we are concerned with how our model output, z, is influenced by changes to our
parameters, q, then we consider the partial derivative of z, ∂z∂q, with respect to q. One approach
to computing this partial derivative is by solving the associated sensitivity equations. Differ-
entiating both sides of the output Eq. (8) with respect to the parameter q yields
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∂z
∂q
¼ ∂g
∂t
∂t
∂q
þ ∂g
∂y
∂y
∂q
þ ∂g
∂q
∂q
∂q
¼ ∂g
∂y
∂y
∂q
þ ∂g
∂q
(9)
since ∂t∂q ¼ 0 and ∂q∂q ¼ 1. The two components ∂g∂y and ∂g∂q can be directly calculated from g, but can
be cumbersome to do by hand depending on the complexity of the function g. Thus, one can
employ automatic differentiation to evaluate these derivatives. Since any mathematical func-
tion can be decomposed into elementary functions, automatic differentiation numerically
implements the chain rule and basic arithmetic equations repeatedly to compute the total
derivative of a function with accuracy to working machine precision [31]. This is achieved with
table lookups and tabulating all the functional compositions [32, 33]. An automatic differenti-
ation (AD) code developed by Martin Fink in MATLAB was employed [34]. Finally, to calcu-
late ∂y∂q, it is noted that y is continuous in t and q. Since
∂y
∂q exists, by taking the partial derivative
with respect to q of the state equations and reversing the order of differentiation [35], we obtain
∂
∂q
dy
dt
 
¼ d
dt
∂y
∂q
 
¼ ∂f
∂t
∂t
∂q
þ ∂f
∂y
∂y
∂q
þ ∂f
∂q
∂q
∂q
¼ ∂f
∂y
∂y
∂q
þ ∂f
∂q
:
(10)
Similar to ∂g∂y and
∂g
∂q,
∂f
∂y and
∂f
∂q are calculated using automatic differentiation. From (10), the
sensitivity equations are given by the following coupled system of differential equations
dy
dt
¼ f t; y; qð Þ,
d
dt
∂y
∂q
 
¼ ∂f
∂q
∂y
∂q
þ ∂f
∂q
:
(11)
Solving the sensitivity equations yields ∂y∂q, which, in turn, gives
∂z
∂q from (9).
3.2.2. Model considerations and sensitivity results
The sensitivities of each parameter are ranked to obtain which parameters are most sensitive.
Since there is a large range of parameter and viral load values, each parameter, qj, is log scaled
in association with the state variable, y, that is,
d log 10 yð Þ
d log 10 qj
  ¼ qj
y
dy
dqj
is considered instead of dydqj. This allows a comparison of the sensitivities of each parameter
using similar magnitudes. The l2 norm is used to nondimensionalize the sensitivities over
time so the following sensitivity coefficient is considered for each parameter
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Sij ¼
∂yi
∂qj




2
¼ 1
tf  t0
ðtf
t0
∂yi
∂qj
qj
maxyi
  !2
dt
2
4
3
5
1
2
: (12)
Eq. (12) is defined to be the relative ranking sensitivity of each variable yi in y with respect to
each individual parameter qj.
Since the local sensitivity analysis depends on values in q, independent sets of parameters that
have a log-normal distribution are created from the population-based model fit in Snoeck et al.
[5]. That is, a sequence of independent parameter sets qk
 	
is generated from this distribution
using the typical values from [5] as the mean. To determine pseudo-global sensitivities, a
sensitivity coefficient, Skij, is computed for each parameter in the k th parameter set. Then, if B
parameter sets are to be analyzed, then an average for all the parameter sets is computed by
Sij ¼ 1B
XB
k¼1
Skij: (13)
A cutoff is determined based on the ranking of the averages attained in (13). Those parameters
above the cutoff are further examined in the identifiability analysis. This method is a version of
what is referred to as Morris Screening in [30]. Similar to the work done here, the Morris
algorithm [36] averages local derivative approximations to provide more global sensitivity
measures. The difference being that the variance in the parameter sets is also considered. Here
that variance would be given by
σ2ij ¼
1
B 1
XB
k¼1
Skij  Sij
 2
: (14)
As explained in [30], while the mean (13) quantifies the individual effect of the input on the
output, the variance (14) estimates the combined effects of the input due to nonlinearities or
interactions with other inputs. The reader is referred to [30, 36] and references therein for a
more detailed analysis of Morris Screening. It is noted that only the marginal distributions are
given in [5], so computations are ignorant of any covariances between parameters. The data
that were used contain only the viral load observations. So the sensitivities of V ¼ VI þ VNI are
of interest. Therefore, (8) is considered where
y ¼ T I VI VNI½ T,
with output
z ¼ V ¼ VI þ VNI :
Two different sets of time points are used during this analysis. The first and second set of time
points come from the partial virologic response (PVR) case and Breakthrough case, respec-
tively. This will provide a better illustration of sensitivities given that treatment decays in the
Breakthrough case, but does not in PVR. The sensitivity rankings are given in Figure 2 for over
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2000 (a) and 400 (b) parameter sets, respectively. Error bars that are two standard deviations
from the mean are included. The sensitive parameters for the PVR and Breakthrough time
points are QPVR ¼ δ; c; β; r; γ
 	
and QBrk ¼ δ; c; β; r; r;γ; ε
 	
, respectively. These parameters are
considered in the identifiability analysis. Note that γ is always considered in the identifiability
analysis due to there not being a value from the literature to fix it to for this model. It is used to
determine whether it affects the identifiability of other parameters.
3.3. Identifiability analysis
After deciding which parameters are sensitive, consideration is given to understanding which
sensitive parameters can uniquely be identified from the data. In this study, we employed a
sensitive-based approach for local identifiability analysis. To this end, we consider the param-
eters contained in q which minimize the cost function
J qð Þ ¼ 1
N
XN
i¼1
Vid  V ti; qð Þ

 2
,
with V ti; qð Þ denoting the model output and Vid denoting the corresponding data value at time
point ti for i ¼ 1,…N, where N is the number of data values. Similar to [37], let us assume that q∗
is the minimum of this cost function. Then by using a Taylor series expansion around q∗, we
obtain
V ti; qð Þ ¼ V ti; q∗ð Þ þ dV ti; q
∗ð Þ
dq
q q∗ð Þ þ…
If we only consider the first two elements of V ti; qð Þ under the assumption that q ≈ q∗ and
substitute this expression into the cost function we find that
Figure 2. Sensitivity rankings using PVR (a) and Breakthrough time points (b).
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J qð Þ ¼ 1
N
XN
i¼1
Vid  V ti; q∗ð Þ 
dV ti; q∗ð Þ
dq
q q∗ð Þ
 2
,
¼ 1
N
XN
i¼1
dV ti; q∗ð Þ
dq
q q∗ð Þ
 2
,
(15)
where we used the fact that q∗ is the minimum of the cost function so that Vid ≈V ti; q
∗ð Þ. Let
S ¼ dV
dq
¼
dV
dq1
t1ð Þ dVdq2
t1ð Þ ⋯ dVdql
t1ð Þ
dV
dq1
t2ð Þ dVdq2
t2ð Þ ⋯ dVdql
t2ð Þ
⋮ ⋮ ⋮ ⋮
dV
dq1
tNð Þ dVdq2
tNð Þ ⋯ dVdql
tNð Þ
2
6666666664
3
7777777775
, (16)
be an N  lð Þ sensitivity matrix relating to the sensitivities dVdqj tið Þ of the output with i ¼ 1,…, N
and j ¼ 1,…, l, where l denotes the number of parameters. The cost function of (15) is rewritten
in terms of this sensitivity matrix
J qð Þ ¼ 1
N
S q q∗ð Þð ÞT S q q∗ð Þð Þ,
¼ 1
N
SΔqð ÞT SΔqð Þ,
where Δq ¼ q q∗. Rearranging Δq ¼ q q∗, we formulate the cost function in terms of
q∗ þ Δq:
J q∗ þ Δqð Þ ¼ 1
N
ΔqTSTSΔq: (17)
If we suppose that Δq is an eigenvector of STS with STSΔq ¼ λΔq, then we have
J q∗ þ Δqð Þ ¼ 1
N
ΔqT λΔqð Þ,
¼ 1
N
λ Δqk k22:
We note that if Δq is an eigenvector with eigenvalue λ ¼ 0, then the cost function to second-
order approximation is J q∗ þ hΔqð Þ ¼ 0: The least squares cost function does not change
values when moving from q∗ to q∗ þ hΔq, with h arbitrary. Thus, the parameters are locally
unidentifiable at q∗. If STS has very small eigenvalues, this can also be a problem
for parameter identification. There have been studies about how the Fisher Information
Matrix (STS) can be used for parameter identification [38, 39]. For example, in [38], they
search all possible parameter combinations and choose them based on the rank of the
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sensitivity matrix, S, and asymptotic standard error uncertainty. We use the following
algorithm as described in [39] to determine which of the parameters in our model will be
unidentifiable.
1. Create the matrix STS, compute its eigenvalues, and order them such that
∣λ1∣ ≤ ∣λ2∣ ≤⋯ ≤ ∣λn∣:
2. If ∣λ1∣ is less than some threshold ε (typically taken to be 104), we say that there is a
parameter that is unidentifiable.
3. The largest magnitude component of the eigenvector Δq1 associated with the eigenvalue
λ1 corresponds to the least identifiable parameter. Remove the corresponding column
from S and repeat step 1.
After performing this procedure, we now have a set of sensitive and locally identifiable
parameters to estimate. The rest of the parameters are set to “typical values” found
in the literature. The identifiability algorithm is applied to all the parameter sets of sensitive
parameters, QPVR and QBrk, obtained in the previous section. It is observed from Figure 3 that
the parameters in QPVR ¼ δ; c; β;γ
 	
are identifiable at least 50% of the time and the parame-
ters in QBrk ¼ δ; c; β;γ; ε
 	
are identifiable at least 50% of the time. The parameters contained
in QPVR and QBrk are those that will be estimated from the clinical data.
4. Parameter estimation
The parameters in QPVR and QBrk are estimated using the weighted sum of squares of errors
(WSSE) given by
Figure 3. Final subset percentages using PVR (a) and Breakthrough time points (b).
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J qð Þ ¼
XN
i¼1
wi log Vid

  log V ti; qð Þð Þ 2, (18)
where wi is the weight for the error term log Vid

  log V ti; qð Þð Þ  at time ti, Vid is data
measurement of viral load at the i th time point and V ti; qð Þ is the model output with param-
eters q. We used both sampling and gradient based methods to minimize this function
implemented in MATLAB. The model was fit to three data sets; namely, PVR, ETR (end-of-
treatment response) and Breakthrough. PVR represents when the patient has an initial positive
reaction to the therapy, but then the viral load rebounds during treatment and never goes
below detection. ETR represents when the viral load drops below detection and does not
rebound. Breakthrough represents when the patient’s viral load drops below detection, but
rebounds. In our data, the LLOQ is 15 IU/ml. When the data drop below the LLOQ, least
squared estimation does not suffice as a statistically rigorous methodology. Instead, we
employ the expectation maximization (EM) [40] to compute maximum likelihood estimates of
our patient specific parameters. For a detailed description of the EM algorithm, we refer the
reader to [41]. The RBV dosage depends on the patient’s body weight and was sometimes
modified during treatment due to different symptoms of the patients such as blood thinning.
The patients experiencing PVR and Breakthrough had constant RBV dosage for the entire
treatment while the patient exhibiting ETR had modified dosage. The RBV efficacy is fixed to
r ¼ :1222 from [22] for the PVR and Breakthrough patients. The efficacies for the ETR patient
were modified based on time, t, in days since initial treatment and are presented in Table 2.
The parameters not in QPVR or QBrk are fixed to the values in Table 3 from [5, 22]. As in [5], the
infected steady state is used for the initial conditions for (7) because the patients considered
had chronic infection. The values in Table 4 are obtained after estimating the parameters in
QPVR and QBrk. These estimates produce the model fits (graphs on the left) and residuals
(graphs on the right) in Figures 4–6. It is noted that in Figure 6, the ETR patient’s viral load
goes to zero, and the residuals for censored data are set to zero.
In practice, the mathematical model is never exact (model misspecification), and the data
contain noise (human errors, instrument errors). Hence, confidence and prediction intervals
are used to understand the extent of uncertainty involved in estimating our parameters. In
Parameter t ≤ 27 27 < t ≤ 83 t > 83
r .5127 .3185 .219
Table 2. Patient ETR’s RBV efficacies based on modified dosage.
Parameters s r Tmax d p ε
Values 6:17 104 .00562 1:85 107 .003 25.1 .6138
Table 3. Fixed parameter values from [5, 22].
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Patient PVR ETR Breakthrough
δ :1883 :0462 .7211 .3293
c 2:717 2:724 11.67 2.089
γ :9987 :0015 .9999 .6575
β 1:875 10-5  1:688 10-5 8:684 10-8 2:259 10-6
ε .6138 .9829 .9875
Table 4. Values from parameter estimation for (7).
Figure 4. Viral load model fit (a) and residual plot (b) for PVR patient data.
Figure 5. Viral load model fit (a) and residual plot (b) for Breakthrough patient data.
Hepatitis C - From Infection to Cure196
calculating these intervals, standard errors are computed from the model predictions using the
parameters that have been estimated. Moreover, 95% parameter and predictive confidence
intervals and prediction intervals for the PVR parameters (attached as half-widths in Table 4)
and predictions are calculated using the asymptotic theory outlined in [22, 27, 30, 41, 42]. The
predictive confidence intervals and prediction intervals are shown in Figure 7.
5.1. Discussion
The higher values in c and δ in the ETR patient lead us to believe that the immune
response along with the drugs has a stronger impact on the mutation and clearance of
the virus. It is known that the immune response is strongly correlated with the clearance
Figure 6. Viral load model fit (a) and residual plot (b) for ETR patient data.
Figure 7. Predictive confidence intervals (a) and prediction intervals (b).
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of the virus. Since the initial conditions of (7) are at the infected steady state, introduction
of the drugs could be a mechanism to jump start the immune response. We note that even
when the virus is not cleared, telaprevir still has a strong impact on viral load decay. This
behavior corresponds with how powerful DAAs can be in reducing viral load even when
it rebounds. The rebound could be because of mutations which are neglected in this
model as stated earlier. There is a dip at around the 150th day in the Breakthrough
response that is unquantifiable due to lack of information regarding the other three states
or a dynamic immune response. However, this type of dip is observed in [5, 27] where
data are available around this time. We conjecture that this dip is due to the immune
response being stimulated by the spike in viral load and infection. The residuals in the
PVR fit in Figure 4 seem to be i.i.d. because the errors seem to be randomly distributed
and are on both sides of the zero axis. This is unlike the Breakthrough fit in Figure 5
which have most of the residuals above the zero axis. The predictive confidence intervals
and prediction intervals look almost the same because the variance is very small, and the
model fits the data very well. The reader is referred to [30] for further details on differ-
ences between the predictive confidence intervals and prediction intervals.
6. Conclusion
The missing data between weeks 12–24, 24–36 and 36–48 for the ETR and Breakthrough
patients make parameter estimation challenging. The predictions would also be more
robust if information concerning states T, I, and VNI were available. These issues should
be considered when making remarks about the estimations and confidence measures.
DAAs were introduced in 2011, so there is not as much data available, but in the future,
we hope for a larger quantity of data to make more precise estimations.
This chapter describes a model for patients with HCV who are treated with IFN, RBV, and
telaprevir combination therapy. The development of this model was motivated by the
desire for a model that can be validated and calibrated using sensitivity and identifiability
techniques while simultaneously incorporating the new DAA, telaprevir. The model can
be used to accurately describe patients exhibiting PVR, ETR, and Breakthrough.
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